BONE BIOLOGICS CORP (BBLG)
US0980705018 - Common Stock
We assign a fundamental rating of 2 out of 10 to BBLG. BBLG was compared to 568 industry peers in the Biotechnology industry. BBLG has a great financial health rating, but its profitability evaluates not so good. BBLG has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BBLG had negative earnings in the past year.
BBLG had a negative operating cash flow in the past year.
In the past 5 years BBLG always reported negative net income.
BBLG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -220.10%, BBLG is doing worse than 91.50% of the companies in the same industry.
The Return On Equity of BBLG (-235.96%) is worse than 69.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -220.1% | ||
| ROE | -235.96% | ||
| ROIC | N/A |
ROA(3y)-93.64%
ROA(5y)N/A
ROE(3y)-119.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BBLG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BBLG has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BBLG has more shares outstanding
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BBLG has an Altman-Z score of -29.62. This is a bad value and indicates that BBLG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -29.62, BBLG is doing worse than 90.62% of the companies in the same industry.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.62 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 14.87 indicates that BBLG has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.87, BBLG belongs to the best of the industry, outperforming 90.09% of the companies in the same industry.
A Quick Ratio of 14.87 indicates that BBLG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 14.87, BBLG belongs to the top of the industry, outperforming 90.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.87 | ||
| Quick Ratio | 14.87 |
3. Growth
3.1 Past
BBLG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.63%, which is quite impressive.
EPS 1Y (TTM)93.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.32%
EPS Next 2Y40.36%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BBLG. In the last year negative earnings were reported.
Also next year BBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BBLG's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y25.35%
5. Dividend
5.1 Amount
No dividends for BBLG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BONE BIOLOGICS CORP
NASDAQ:BBLG (12/20/2024, 8:00:01 PM)
After market: 0.97 -0.04 (-3.96%)1.01
-0.04 (-3.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.31%
Inst Owner Change42%
Ins Owners513.95%
Ins Owner Change0%
Market Cap2.48M
Analysts82.86
Price Target17.09 (1592.08%)
Short Float %2.95%
Short Ratio0.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-117.26%
Min EPS beat(2)-287.25%
Max EPS beat(2)52.74%
EPS beat(4)3
Avg EPS beat(4)-23.66%
Min EPS beat(4)-287.25%
Max EPS beat(4)83.1%
EPS beat(8)6
Avg EPS beat(8)-18.28%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)91.5%
EPS NQ rev (3m)91.5%
EPS NY rev (1m)-57.73%
EPS NY rev (3m)-57.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.66 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.82
EYN/A
EPS(NY)-1.99
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -220.1% | ||
| ROE | -235.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-93.64%
ROA(5y)N/A
ROE(3y)-119.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.87 | ||
| Quick Ratio | 14.87 | ||
| Altman-Z | -29.62 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.43%
EPS Next Y92.32%
EPS Next 2Y40.36%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-156.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-164.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-164.49%
OCF growth 3YN/A
OCF growth 5YN/A